The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a weight-loss drug.

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Two reasons to buy the stock: Its cardiometabolic pipeline is shaping up and moving forward Amgen is keen to launch a drug to give it some exposure to the anti-obesity drug gold rush that's going on ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.

FILE PHOTO: Illustration shows test tubes with "Mpox virus positive" label WASHINGTON (Reuters) - A case of clade of I mpox ...